Effector Therapeutics Valuation
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Effector Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Effector Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 23.71 %, shares owned by insiders of 2.90 %, and Current Valuation of (4.52 M) as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Effector Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Effector Therapeutics is based on 3 months time horizon. Increasing Effector Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Effector stock is determined by what a typical buyer is willing to pay for full or partial control of Effector Therapeutics. Since Effector Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Effector Stock. However, Effector Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.13 | Real 0.12 | Hype 0.13 |
The intrinsic value of Effector Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Effector Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Effector Therapeutics helps investors to forecast how Effector stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Effector Therapeutics more accurately as focusing exclusively on Effector Therapeutics' fundamentals will not take into account other important factors: Effector Therapeutics Total Value Analysis
Effector Therapeutics is currently anticipated to have valuation of (4.52 M) with market capitalization of 846.79 K, debt of 19.45 M, and cash on hands of 41.04 M. The negative valuation of Effector Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Effector Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.52 M) | 846.79 K | 19.45 M | 41.04 M |
Effector Therapeutics Asset Utilization
One of the ways to look at asset utilization of Effector is to check how much profit was generated for every dollar of assets it reports. Effector Therapeutics shows a negative utilization of assets of -0.83 percent, losing $0.008333 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Effector Therapeutics shows how discouraging it operates for each dollar spent on its assets.Effector Therapeutics Ownership Allocation
Roughly 73.39 percent of Effector Therapeutics outstanding shares are held by general public with 2.9 (percent) owned by insiders and only 23.71 % by other corporate entities.Effector Therapeutics Profitability Analysis
Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M).About Effector Therapeutics Valuation
The delisted stock valuation mechanism determines Effector Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Effector Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Effector Therapeutics. We calculate exposure to Effector Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Effector Therapeutics's related companies.eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Effector Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Effector Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.2 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world |